Clinical trials: Advanced Disease
Melanoma
Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma
The purpose of this study is to assess the safety profile of vemurafenib, 960 mg, administered for 6 weeks, followed by ipilimumab monotherapy in patients with BRAF V600 mutated advanced/metastatic melanoma.
- Trial name
- NCT01673854
- Testing
- Ipilimumab, Vemurafenib
- Where
- 14 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Inflammatory Breast Cancer, Male Breast Cancer
Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
This phase II trial studies how well giving sunitinib malate together with paclitaxel, doxorubicin hydrochloride, and cyclophosphamide before surgery works in treating patients with stage IIB-IIIC breast cancer.
- Conditions
- Inflammatory Breast Cancer, Male Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer
- Trial name
- NCT00513695
- Testing
- sunitinib malate, paclitaxel, doxorubicin hydrochloride
- Where
- 7 sites in United States
- Volunteers
- 68 people
- Sponsor
- University of Washington
Cervical Cancer
Tirapazamine, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer
RATIONALE: Drugs used in chemotherapy, such as tirapazamine and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00098995
- Testing
- cisplatin, tirapazamine, brachytherapy
- Where
- 2 sites in Australia, Canada
- Volunteers
- 22 people
- Sponsor
- Peter MacCallum Cancer Centre, Australia
Hepatocellular Carcinoma
Transarterial Chemotherapy Compared With Oral Chemotherapy in the Treatment of Advanced Hepatocellular Carcinoma
In India, majority of our patients have advanced hepatocellular carcinoma (HCC) at presentation and hence are unsuitable for the available curative treatment options. In such patients the treatment options are mainly palliative.
- Trial name
- NCT02240771
- Testing
- Transarterial chemotherapy, Oral chemotherapy
- Where
- India
- Volunteers
- 124 people
- Sponsor
- All India Institute of Medical Sciences
Pneumonia, Pneumocystis Carinii, HIV Infections
A Study of Three Drugs Plus Zidovudine in the Prevention of Infections in HIV-Infected Patients
To evaluate and compare 3 anti-pneumocystis regimens plus zidovudine (AZT) in persons with HIV infection and T4 cell count less than 200 cells/mm3.
- Trial name
- NCT00000991
- Testing
- Pentamidine isethionate, Sulfamethoxazole-Trimethoprim, Dapsone
- Where
- 21 sites in United States, Tanzania
- Volunteers
- 600 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Voice Disorders, Neurologic Disorder
Voice Analysis in Patients With Neurologic Diseases
In this observational pilot study, the investigators will record and assess voice samples from healthy participants and those participants affected by neurologic diseases to evaluate possible differences in voice features.
- Trial name
- NCT04846413
- Testing
- Speech task
- Where
- Italy
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Neuromed IRCCS
Non-Hodgkin's Lymphoma
LSA4 Protocol for the Treatment of Advanced Pediatric and Adolescent Non-Hodgkins Lymphoma
Non-Hodgin's lymphoma is curable in 76% of patients. In nonlymphoblastic lymphmas, cancer may return on average 3 months from beginning treatment and for lymphoblastic lymphomas, 6 months.
- Trial name
- NCT00610883
- Testing
- LSA4, Cyclophosphamide, Methotrexate, Daunomycin, L-asparaginase, BCNU
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft Versus Host Disease, Leukemia
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining chemotherapy with bone marrow transplantation may allow the doctor to give higher doses of…
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
- Trial name
- NCT00014469
- Testing
- busulfan, melphalan, methotrexate
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Solid Tumors
A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors (8669-028)(COMPLETED)
Ridaforolimus (Deforolimus, AP23573, MK-8669) is an mTor inhibitor shown to have promising activity in adults with a variety of solid malignancies, particularly the sarcomas.
- Trial name
- NCT00704054
- Testing
- ridaforolimus
- Volunteers
- 15 people
- Sponsor
- Merck Sharp & Dohme LLC
Centronuclear Myopathy
Multispectral Optoacoustic Tomography for Advanced Imaging of Centronuclear Myopathy
Twenty patients with centronuclear myopathy and twenty age- and sex-matched, muscle-healthy controls will undergo diagnostic examination.
- Trial name
- MOSAIC (NCT07021820)
- Testing
- MSOT
- Where
- Germany
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Erlangen-Nürnberg Medical School
Breast Cancer Stage IV
RWS of Paclitaxel Liposome Combined With Anti-HER-2 Monoclonal Antibody
This is a retrospective, single-arm real-world study based on the National Anticancer Drug Clinical Application Monitoring Network database.The aim of this study is to evaluate the efficacy and safety of paclitaxel liposome…
- Trial name
- NCT06481553
- Testing
- first line treatment
- Where
- China
- Volunteers
- 480 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Thyroid Cancer
Anlotinib Neoadjuvant Treatment in Locally Advanced Thyroid Cancer
To determine the efficacy and safety of Anlotinib in patients of locally advanced thyroid cancer in the neoadjuvant setting.
- Trial name
- NCT04309136
- Testing
- Anlotinib, surgery, core needle biopsy
- Where
- China
- Volunteers
- 13 people
- Sponsor
- Fudan University
Dementia, Paratonia
Safety and Effectiveness of Botulinum Toxin in Elderly Patients With Dementia and Muscle Stiffness
Aim of the study is to perform a pilot study to assess the impact of Botulinum toxin on muscle tone, and caregiver burden in individuals who are cognitively impaired and who are fully dependent.
- Trial name
- NCT02212119
- Testing
- Botulinum Toxin, Saline
- Where
- Canada
- Volunteers
- 10 people
- Sponsor
- Assistive Technology Clinic, Canada
Advanced Cancer
Observational Study of Incidence of Breakthrough Cancer Pain and How it is Treated
The purpose of this study is to describe how often advanced cancer patients experience breakthrough pain (BTcP), and to describe how this pain is treated, and how effective these treatments are.
- Trial name
- Break-1 (NCT02069067)
- Where
- 3 sites in Italy
- Volunteers
- 500 people
- Sponsor
- National Cancer Institute, Naples
Pancreatic Carcinoma
L-CARnitine in the Palliative Treatment of Advanced PANcreatic Cancer (CARPAN)
The study investigated the role of L-Carnitine supplementation on proinflammatory immune response, malnutrition, cancer cachexia and cancer related fatigue in advanced and inoperable pancreatic cancer, UICC Stage IV .
- Trial name
- CARPAN (NCT01330823)
- Testing
- L-Carnitine
- Where
- Germany
- Volunteers
- 72 people
- Sponsor
- University Medicine Greifswald
Epithelial Ovarian Cancer
Seprafilm™ for the Prevention of Intraperitoneal Adhesions and Improved Delivery of Therapy in Women Undergoing Staging and Intraperitoneal Chemotherapy for Advanced Ovarian Cancer
The purpose of this research is to determine if a film to prevent adhesions will improve the area of distribution of a contrast dye (representative of chemotherapy) in the abdominal cavity (belly) of women who have undergone…
- Trial name
- NCT01095367
- Testing
- Seprafilm™
- Where
- 2 sites in United States, Canada
- Volunteers
- 15 people
- Sponsor
- University of British Columbia
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of cancer of the urinary tract.
- Conditions
- Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
- Trial name
- NCT00014144
- Testing
- gefitinib
- Where
- 95 sites in United States
- Volunteers
- 31 people
- Sponsor
- SWOG Cancer Research Network
HIV Infections
A Study of Enfuvirtide (Fuzeon) in Participants With Advanced Human Immunodeficiency Virus (HIV) Infection
This study assessed the safety and tolerability of enfuvirtide in participants with advanced HIV genotype 1 (HIV-1) disease. Eligible participants who failed treatment with regimens containing at least one product from each…
- Trial name
- NCT02582983
- Testing
- Enfuvirtide
- Where
- 5 sites in Thailand
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Solid Tumor, Hematologic Malignancy
GSL Synthetase Inhibitor in Combination With Immune Checkpoint Inhibitor in Previously Treated Blood and Solid Tumor
Immune checkpoint blockade has made great but unsatisfied success in treating cancers. One important reason is the hijacked HLA (Human Leukocyte Antigen) antigen presentation.
- Trial name
- NCT04944888
- Testing
- Eliglustat, Immune checkpoint inhibitor
- Where
- China
- Volunteers
- 31 people
- Sponsor
- Chinese PLA General Hospital
Hepatocellular Carcinoma, Liver Cancer
First-in-Human Safety, Tolerability and Antitumour Activity Study of MTL-CEBPA in Patients With Advanced Liver Cancer
MNA-3521-011 study is a multi-centre, open-label, first-in-human, phase 1a/b clinical study dose/dose frequency escalation followed by a cohort expansion part.
- Trial name
- OUTREACH (NCT02716012)
- Testing
- MTL-CEBPA, Sorafenib 200mg
- Where
- 11 sites in Singapore, Taiwan and 1 more
- Volunteers
- 75 people
- Sponsor
- Mina Alpha Limited